Not recruiting

Study on PRAX-628 for Adults with Focal Epilepsy Taking 1 to 3 Anti-Seizure Medications

Fast replyInvestigationalNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a new treatment for Focal Epilepsy, a condition characterized by seizures that originate in one specific area of the brain. The treatment being tested is a medication called PRAX-628, which is taken in capsule form. The study will compare the effects of PRAX-628 to a placebo to determine its effectiveness in reducing the frequency of seizures in adults who are already taking one to three anti-seizure medications.

The purpose of the study is to evaluate how well PRAX-628 works in reducing the number of seizures experienced by participants. The study will be conducted over a period of several weeks, during which participants will be randomly assigned to receive either PRAX-628 or a placebo. Participants will continue their current anti-seizure medications throughout the study. The trial will involve regular monitoring and assessments to track changes in seizure frequency and any side effects experienced by participants.

Participants will be asked to keep a diary of their seizures and attend scheduled visits for assessments. The study aims to provide valuable information on the safety and effectiveness of PRAX-628 as a potential treatment option for individuals with Focal Epilepsy. This research could lead to improved management of seizures for those affected by this condition.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Screening and observation period
During this period, you will be asked to keep a seizure diary for 9 weeks. This involves recording any seizures you experience, ensuring that you document them on at least 80% of the days.
You must have at least 8 countable focal seizures during this time. Countable focal seizures include those with clear signs, those with impaired awareness, or those that spread to both sides of the brain.
You should not be seizure-free for more than 21 consecutive days during this period.
Step 2
Randomization
After the screening period, you will be randomly assigned to receive either the PRAX-628 medication or a placebo. A placebo is a substance with no active medication, used to compare effects.
Step 3
Treatment period
You will take the assigned medication orally in the form of a capsule. The specific dosage and frequency will be provided by the study team.
This period will last for a specified duration, during which you will continue to record your seizures in the diary.
Step 4
Follow-up assessments
Throughout the trial, you will undergo regular assessments to monitor your health and the effects of the medication. This includes checking vital signs, laboratory tests, and other evaluations as needed.
You will also be asked about any side effects or changes in your condition.
Step 5
End of trial
At the end of the trial, you will have a final assessment to evaluate the overall impact of the treatment on your seizure frequency and health.
The results will help determine the effectiveness and safety of PRAX-628 for treating focal seizures.

Who can join the trial?

10 criteria

The participant must be willing to sign a document that shows they understand the purpose of the clinical trial and agree to follow all the procedures and assessments required during the trial.
The participant must be between the ages of 18 and 75 at the time they agree to join the study.
The participant must have a diagnosis of focal onset epilepsy, which is a type of epilepsy where seizures start in one area of the brain.
Before joining the study, the participant must have had a CT or MRI scan that shows their epilepsy is not caused by a condition that is getting worse.
The participant must be taking stable doses of 1 to 3 anti-seizure medications (ASMs) for at least 4 weeks before the study starts. ASMs are drugs used to control seizures.
check
The participant must report having at least 4 countable focal onset seizures in the 4 weeks before the study starts and record at least 8 countable focal onset seizures during the observation period. Countable focal seizures include:
- Focal aware seizures with clear observable signs
- Focal seizures with impaired awareness
- Focal to bilateral tonic-clonic seizures, which are seizures that start in one part of the brain and spread to both sides, causing convulsions.
- The participant must complete a seizure diary on at least 80% of the days during the observation period.
- The participant must not be seizure-free for more than 21 consecutive days during the 9-week observation period. The pattern of seizures will be checked to ensure they are not only having clusters of seizures.

Who cannot join the trial?

4 criteria

Patients who do not have Focal Epilepsy cannot participate.
Patients who are not currently taking 1 to 3 Anti-Seizure Medications (ASMs) cannot participate. ASMs are drugs used to control seizures.
Patients who are younger than 18 years old or older than 65 years old cannot participate.
Patients who are part of a vulnerable population, such as those unable to give consent, cannot participate.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Verified
Azienda Ospedaliera Universitaria Di Cagliari
Monserrato, Italy
Responsive
Futuremeds Sp. z o.o.
Wroclaw, Poland
Responsive
Universita Degli Studi Di Roma La Sapienza
Rome, Italy

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

PRAX-628 is a medication being studied for its ability to help reduce the frequency of focal seizures in adults. Focal seizures are a type of seizure that starts in one area of the brain. This medication is being tested to see if it can be an effective treatment for people who are already taking one to three other anti-seizure medications. The goal is to see if adding PRAX-628 can help control seizures better than the current treatment alone.

Prax-628

What is already known about the treatment

PRAX-628 – PRAX-628 is an investigational medication currently being studied for its potential to help adults with focal epilepsy, a condition characterized by seizures that originate in a specific area of the brain. It is administered orally, meaning it is taken by mouth in the form of a pill or liquid. The main goal of the ongoing clinical trial is to determine how well PRAX-628 can reduce the frequency of these seizures compared to a placebo, which is a substance with no active medication. At the molecular level, PRAX-628 is believed to work by modulating certain brain receptors to stabilize nerve activity, which may help prevent seizures. It falls under the pharmacological classification of antiepileptic drugs, which are used to manage and treat seizure disorders.

Investigated diseases

Focal Epilepsy – Focal epilepsy is a neurological condition characterized by recurrent seizures that originate in a specific area of the brain. These seizures can affect sensory perception, motor skills, or consciousness, depending on the brain region involved. The progression of focal epilepsy can vary, with some individuals experiencing an increase in seizure frequency or severity over time. Seizures may start with an aura, a warning sign that can include unusual sensations or emotions. As the condition progresses, seizures can become more complex, potentially spreading to other areas of the brain. The impact on daily life can vary widely among individuals, depending on the frequency and severity of the seizures.